The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL trial and promised to share more at an upcoming scientific meeting.

The phase 3 trial randomized 260 people with anti-acetylcholine receptor antibody-positive gMG to take gefurulimab or placebo. After 26 weeks, people on gefurulimab performed significantly better on a ...